Table 2.

Reduction in tumor IFP in animal and human tumors after antiangiogenic treatment

IFP before treatment (mean ± SE, mm Hg)IFP after treatment (mean ± SE, mm Hg)Ref.
IFP in human tumors
    Rectal carcinoma treated with 5 mg/kg bevacizumab15 ± 0.50 (n = 4)4 ± 0.55 (n = 4)( 27)
    Rectal carcinoma treated with 10 mg/kg bevacizumab15.8 ± 2.0 (n = 5)5.4 ± 0.85 (n = 5)( 29)
IFP in animal models
    Spontaneous tumor grown in C3H mice treated with DC10111.4 ± 0.55 (n = 4)4.63 ± 0.50 (n = 4)( 52)
    MCaIV murine mammary carcinoma treated with DC1016.13 ± 1.0 (n = 5)3.10 ± 0.52 (n = 5)( 26)
    54A human small cell lung carcinoma xenograft treated with DC10112.03 ± 2.29 (n = 5)6.2 ± 0.97 (n = 5)( 26)
    U87 human glioblastoma xenograft treated with DC10111.52 ± 1.89 (n = 5)5.95 ± 1.06 (n = 5)( 26)
    LS174T human colon adenocarcinoma xenograft treated with bevacizumab13.5 ± 4.0 (n = 8)3.5 ± 1.0 (n = 8)( 25)
    U87 human glioblastoma xenograft treated with bevacizumab12.0 ± 3.0 (n = 8)3.0 ± 1.5 (n = 8)( 25)